首页 > 最新文献

中华胃肠外科杂志最新文献

英文 中文
[Prognosis and its influencing factors in patients with non-gastric gastrointestinal stromal tumors at low risk of recurrence: a retrospective multicenter study in China]. [中国非胃肠道间质瘤低复发风险患者的预后及其影响因素:一项多中心回顾性研究]。
Q3 Medicine Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn441530-20240904-00303
L X Yang, W L Yang, X Wu, P Zhang, B Zhang, J J Ma, X H Zhang, H R Qian, Y Zhou, T Chen, H Xu, G L Gu, Z D Gao, G Zhai, X F Sun, C Q Jing, H B Qiu, X D Gao, H Cao, M Wang
<p><p><b>Objective:</b> To investigate the prognosis and the factors that influence it in patients with non-gastric gastrointestinal stromal tumors (GISTs) who are at low risk of recurrence. <b>Methods:</b> This was a retrospective cohort study. Clinicopathologic and prognostic data from patients with non-gastric GISTs and at low risk of recurrence (i.e., very low-risk or low-risk according to the 2008 version of the Modified NIH Risk Classification), who attended 18 medical centers in China between January 2000 and June 2023, were collected. We excluded patients with a history of prior malignancy, concurrent primary malignancy, multiple GISTs, and those who had received preoperative imatinib. The study cohort comprised 1,571 patients with GISTs, 370 (23.6%) of whom were at very low-risk and 1,201 (76.4%) at low-risk of recurrence. The cohort included 799 (50.9%) men and 772 (49.1%) women of median age 57 (16-93) years. Patients were followed up to July 2024. The prognosis and its influencing factors were analyzed. Receiver operating characteristic curves for tumor diameter and Ki67 were established, and the sensitivity, specificity, area under the curve (AUC) and optimal cut-off value with 95% confidence intervals were calculated. Propensity score matching was implemented using the 1:1 nearest neighbor matching method with a matching tolerance of 0.02. <b>Results:</b> With a median follow-up of 63 (12-267) months, the 5- and 10-year overall survival (OS) rates of the 1,571 patients were 99.5% and 98.0%, respectively, and the 5- and 10-year disease-free survival (DFS) rates were 96.3% and 94.4%, respectively. During postoperative follow-up, 3.8% (60/1,571) patients had disease recurrence or metastasis, comprising 0.8% (3/370) in the very low-risk group and 4.7% (57/1,201) in the low-risk group. In the low-risk group, recurrence or metastasis occurred in 5.5% (25/457) of patients with duodenal GISTs, 3.9% (25/645) of those with small intestinal GISTs, 9.2% (6/65) of those with rectal GISTs, and 10.0% (1/10) of those with colonic GISTs. Among the 60 patients with metastases, 56.7% (34/60) of the metastases were located in the abdominal cavity, 53.3% (32/60) in the liver, and 3.3% (2/60) in bone. During the follow-up period, 13 patients (0.8%) died of disease. Receiver operating characteristic curves were plotted for tumor diameter and Ki67 and assessed using the Jordon index. This showed that the difference in DFS between the two groups was statistically significant when the cutoff value for tumor diameter was 3.5 cm (AUC 0.731, 95% CI: 0.670-0.793, sensitivity 77.7%, specificity 64.1%). Furthermore, the difference in DFS between the two groups was statistically significant when the cutoff value for Ki67 was 5% (AUC 0.693, 95% CI: 0.624-0.762, sensitivity 60.7%, specificity 65.3%). Multifactorial analysis revealed that tumor diameter ≥3.5 cm, Ki67 ≥5%, and R1 resection were independent risk factors for DFS in patients with non-gastric GISTs at low
研究目的研究低复发风险的非胃肠道间质瘤(GIST)患者的预后及其影响因素。研究方法这是一项回顾性队列研究。研究收集了2000年1月至2023年6月期间在中国18家医疗中心就诊的非胃癌GIST低复发风险患者(即根据2008年版《美国国立卫生研究院风险分类》(Modified NIH Risk Classification)划分的极低风险或低风险患者)的临床病理和预后数据。我们排除了既往有恶性肿瘤病史、同时患有原发性恶性肿瘤、多发性 GIST 以及术前接受过伊马替尼治疗的患者。研究队列包括1571名GIST患者,其中370人(23.6%)为极低风险,1201人(76.4%)为低复发风险。队列中包括799名男性(50.9%)和772名女性(49.1%),中位年龄为57(16-93)岁。患者随访至2024年7月。对预后及其影响因素进行了分析。建立了肿瘤直径和Ki67的接收者操作特征曲线,并计算了灵敏度、特异性、曲线下面积(AUC)和最佳临界值及95%置信区间。采用 1:1 近邻匹配法进行倾向评分匹配,匹配公差为 0.02。结果中位随访时间为 63(12-267)个月,1571 名患者的 5 年和 10 年总生存率(OS)分别为 99.5% 和 98.0%,5 年和 10 年无病生存率(DFS)分别为 96.3% 和 94.4%。术后随访期间,3.8%(60/1,571)的患者出现疾病复发或转移,其中极低风险组为0.8%(3/370),低风险组为4.7%(57/1,201)。在低风险组中,5.5%(25/457)的十二指肠GIST患者、3.9%(25/645)的小肠GIST患者、9.2%(6/65)的直肠GIST患者和10.0%(1/10)的结肠GIST患者出现复发或转移。在有转移灶的 60 名患者中,56.7%(34/60)的转移灶位于腹腔,53.3%(32/60)位于肝脏,3.3%(2/60)位于骨骼。在随访期间,13 名患者(0.8%)因病死亡。我们绘制了肿瘤直径和Ki67的接收者操作特征曲线,并使用乔登指数进行了评估。结果显示,当肿瘤直径的临界值为 3.5 厘米时,两组患者的 DFS 差异具有统计学意义(AUC 0.731,95% CI:0.670-0.793,敏感性 77.7%,特异性 64.1%)。此外,当 Ki67 的临界值为 5%时,两组患者的 DFS 差异具有统计学意义(AUC 0.693,95% CI:0.624-0.762,敏感性 60.7%,特异性 65.3%)。多因素分析显示,肿瘤直径≥3.5厘米、Ki67≥5%和R1切除术是低复发风险非胃部GIST患者DFS的独立危险因素(均为P57年),Ki67≥5%和R1切除术也是低复发风险非胃部GIST患者OS的独立危险因素(均为PP>0.05)。伊马替尼治疗时间少于1年组的10年DFS和OS分别为87.5%和95.5%,治疗时间超过1年组的10年DFS和OS分别为88.5%和97.8%。伊马替尼治疗时间少于3年组的10年DFS和OS分别为89.6%和92.6%,伊马替尼治疗时间超过3年组的10年DFS和OS分别为88.0%和100.0%。结论原发性、非胃部、低复发风险 GIST 的总体预后相对较好;但也会出现复发和转移。年龄、肿瘤直径、Ki67 和 R1 切除术可能会影响预后。对于一些低复发风险的 GIST 患者,在适当的时间内使用伊马替尼进行辅助治疗,可能有助于预防复发和提高生存率。
{"title":"[Prognosis and its influencing factors in patients with non-gastric gastrointestinal stromal tumors at low risk of recurrence: a retrospective multicenter study in China].","authors":"L X Yang, W L Yang, X Wu, P Zhang, B Zhang, J J Ma, X H Zhang, H R Qian, Y Zhou, T Chen, H Xu, G L Gu, Z D Gao, G Zhai, X F Sun, C Q Jing, H B Qiu, X D Gao, H Cao, M Wang","doi":"10.3760/cma.j.cn441530-20240904-00303","DOIUrl":"10.3760/cma.j.cn441530-20240904-00303","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the prognosis and the factors that influence it in patients with non-gastric gastrointestinal stromal tumors (GISTs) who are at low risk of recurrence. &lt;b&gt;Methods:&lt;/b&gt; This was a retrospective cohort study. Clinicopathologic and prognostic data from patients with non-gastric GISTs and at low risk of recurrence (i.e., very low-risk or low-risk according to the 2008 version of the Modified NIH Risk Classification), who attended 18 medical centers in China between January 2000 and June 2023, were collected. We excluded patients with a history of prior malignancy, concurrent primary malignancy, multiple GISTs, and those who had received preoperative imatinib. The study cohort comprised 1,571 patients with GISTs, 370 (23.6%) of whom were at very low-risk and 1,201 (76.4%) at low-risk of recurrence. The cohort included 799 (50.9%) men and 772 (49.1%) women of median age 57 (16-93) years. Patients were followed up to July 2024. The prognosis and its influencing factors were analyzed. Receiver operating characteristic curves for tumor diameter and Ki67 were established, and the sensitivity, specificity, area under the curve (AUC) and optimal cut-off value with 95% confidence intervals were calculated. Propensity score matching was implemented using the 1:1 nearest neighbor matching method with a matching tolerance of 0.02. &lt;b&gt;Results:&lt;/b&gt; With a median follow-up of 63 (12-267) months, the 5- and 10-year overall survival (OS) rates of the 1,571 patients were 99.5% and 98.0%, respectively, and the 5- and 10-year disease-free survival (DFS) rates were 96.3% and 94.4%, respectively. During postoperative follow-up, 3.8% (60/1,571) patients had disease recurrence or metastasis, comprising 0.8% (3/370) in the very low-risk group and 4.7% (57/1,201) in the low-risk group. In the low-risk group, recurrence or metastasis occurred in 5.5% (25/457) of patients with duodenal GISTs, 3.9% (25/645) of those with small intestinal GISTs, 9.2% (6/65) of those with rectal GISTs, and 10.0% (1/10) of those with colonic GISTs. Among the 60 patients with metastases, 56.7% (34/60) of the metastases were located in the abdominal cavity, 53.3% (32/60) in the liver, and 3.3% (2/60) in bone. During the follow-up period, 13 patients (0.8%) died of disease. Receiver operating characteristic curves were plotted for tumor diameter and Ki67 and assessed using the Jordon index. This showed that the difference in DFS between the two groups was statistically significant when the cutoff value for tumor diameter was 3.5 cm (AUC 0.731, 95% CI: 0.670-0.793, sensitivity 77.7%, specificity 64.1%). Furthermore, the difference in DFS between the two groups was statistically significant when the cutoff value for Ki67 was 5% (AUC 0.693, 95% CI: 0.624-0.762, sensitivity 60.7%, specificity 65.3%). Multifactorial analysis revealed that tumor diameter ≥3.5 cm, Ki67 ≥5%, and R1 resection were independent risk factors for DFS in patients with non-gastric GISTs at low ","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 11","pages":"1123-1132"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Relationship between ripretinib concentration and the prognosis of advanced gastrointestinal stromal tumors in China: a multicenter study]. [瑞瑞替尼浓度与中国晚期胃肠道间质瘤预后的关系:一项多中心研究]。
Q3 Medicine Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn441530-20240725-00258
H Xu, X F Sun, H R Qian, M Wang, X Wu, Y Zhou, F Wang, L N Sun, Y Q Wang, F Y Li, Q Zhang, Z K Xu
<p><p><b>Objective:</b> To investigate the prognosis and safety of ripretinib in the treatment of patients with advanced gastrointestinal mesenchymal stromal tumors (GISTs) and to analyze the relationship between blood concentrations of this drug and prognosis. <b>Methods:</b> In this retrospective study, we investigated the effects of ripretinib in patients with advanced GISTs. The inclusion criteria comprised: (1) daily oral administration of ripretinib scheduled; and (2) uninterrupted treatment for at least 1month, with a stable and relatively fixed daily dosage maintained for a minimum of 2 weeks. Exclusion criteria comprised concurrent use of other tyrosine kinase inhibitors and presence of significant organ dysfunction. We retrospectively identified 79 patients with advanced GISTs who had received ripretinib across seven medical centers, namely Jiangsu Provincial Hospital, Jiangsu Cancer Hospital, Nanjing Drum Tower Hospital Affiliated to Nanjing University, Sir Run Run Shaw Hospital of Zhejiang University, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and the General Hospital of the People's Liberation Army, from 1 June 2021 to 31 March 2024. The cohort included 48 men and 31 women, 19 of whom had received ripretinib as second-line, 13 as third-line, and 47 as fourth-line therapy. Two peripheral venous blood samples were obtained from each participant and high-performance liquid chromatography-tandem mass spectrometry used to determine peak (Cmax) and trough (Cmin) concentrations of ripretinib. Machine learning methodologies, specifically the K-nearest neighbor algorithm combined with the Gridsearch CV strategy, were employed to establish the threshold for Cmin. We analyzed adverse reactions, treatment efficacy, median progression-free survival (mPFS), and the relationship between drug blood concentration and selected clinical parameters. <b>Results:</b> In the entire cohort, the Cmin and Cmax of ripretinib were 467 ± 360 μg/L and 986 ± 493 μg/L, respectively. Notably, female patients and individuals in the high-dose group exhibited significantly higher values for both Cmin and Cmax (both <i>P</i><0.05). However, variations in drug concentrations associated with the line of ripretinib therapy, treatment efficacy, disease progression, and presence of selected specific genetic mutations were not significantly associated with values of Cmin and Cmax (<i>P</i>>0.05). Among the 79 patients with advanced GISTs receiving ripretinib, reported adverse reactions included alopecia (53, 67.09%), hand-foot syndrome (24, 30.38%), fatigue (22, 27.85%), and myalgia (21, 26.58%). Two patients (2.53%) had grade III complications, both classified as hand-foot syndrome. The correlation between Cmax and adverse reactions was not statistically significant (<i>P</i> > 0.05). By the time of the latest follow-up, five deaths (6.3%) had occurred within the cohort. The mPFS for the group was 16.3 months, with a mPFS of 14.4 months fo
目的研究瑞培替尼(ripretinib)治疗晚期胃肠间质瘤(GIST)患者的预后和安全性,并分析该药物的血药浓度与预后之间的关系。研究方法在这项回顾性研究中,我们调查了瑞瑞替尼对晚期胃肠间质瘤患者的影响。纳入标准包括:(1) 每天按计划口服瑞瑞替尼;(2) 不间断治疗至少 1 个月,且每日剂量稳定且相对固定,至少维持 2 周。排除标准包括同时使用其他酪氨酸激酶抑制剂和存在严重器官功能障碍。我们从2021年6月1日至2024年3月31日,在江苏省立医院、江苏省肿瘤医院、南京大学附属鼓楼医院、浙江大学附属邵逸夫医院、上海交通大学医学院附属仁济医院和中国人民解放军总医院等7家医疗中心,回顾性地发现了79例接受过瑞瑞替尼治疗的晚期GIST患者。研究对象包括48名男性和31名女性,其中19人接受过瑞瑞替尼二线治疗,13人接受过瑞瑞替尼三线治疗,47人接受过瑞瑞替尼四线治疗。研究人员采集了每位参与者的两份外周静脉血样本,并使用高效液相色谱-串联质谱法测定了瑞格列替尼的峰值(Cmax)和谷值(Cmin)浓度。我们采用了机器学习方法,特别是 K 近邻算法与 Gridsearch CV 策略相结合,来确定 Cmin 的阈值。我们分析了不良反应、疗效、中位无进展生存期(mPFS)以及药物血药浓度与部分临床参数之间的关系。结果在整个队列中,瑞瑞替尼的Cmin和Cmax分别为467 ± 360 μg/L和986 ± 493 μg/L。值得注意的是,女性患者和高剂量组患者的Cmin和Cmax值明显更高(PP均大于0.05)。在接受瑞瑞替尼治疗的79例晚期GIST患者中,报告的不良反应包括脱发(53例,67.09%)、手足综合征(24例,30.38%)、疲劳(22例,27.85%)和肌痛(21例,26.58%)。两名患者(2.53%)出现了 III 级并发症,均为手足综合征。Cmax与不良反应之间的相关性无统计学意义(P > 0.05)。到最近一次随访时,组群中有五人死亡(6.3%)。该组的 mPFS 为 16.3 个月,其中接受标准剂量治疗的患者的 mPFS 为 14.4 个月,接受递增剂量治疗的患者的 mPFS 为 7.0 个月。在65名接受标准剂量瑞瑞替尼治疗的患者中,Cmin超过450微克/升阈值的患者的mPFS明显更长(18.0个月 vs. 13.7个月;P < 0.05)。结论在中国,晚期GIST患者对瑞瑞替尼表现出明显的耐受性,没有证据表明不良反应与该药的Cmax之间存在相关性。此外,Cmin超过450 μg/L可能与mPFS延长有关。
{"title":"[Relationship between ripretinib concentration and the prognosis of advanced gastrointestinal stromal tumors in China: a multicenter study].","authors":"H Xu, X F Sun, H R Qian, M Wang, X Wu, Y Zhou, F Wang, L N Sun, Y Q Wang, F Y Li, Q Zhang, Z K Xu","doi":"10.3760/cma.j.cn441530-20240725-00258","DOIUrl":"10.3760/cma.j.cn441530-20240725-00258","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the prognosis and safety of ripretinib in the treatment of patients with advanced gastrointestinal mesenchymal stromal tumors (GISTs) and to analyze the relationship between blood concentrations of this drug and prognosis. &lt;b&gt;Methods:&lt;/b&gt; In this retrospective study, we investigated the effects of ripretinib in patients with advanced GISTs. The inclusion criteria comprised: (1) daily oral administration of ripretinib scheduled; and (2) uninterrupted treatment for at least 1month, with a stable and relatively fixed daily dosage maintained for a minimum of 2 weeks. Exclusion criteria comprised concurrent use of other tyrosine kinase inhibitors and presence of significant organ dysfunction. We retrospectively identified 79 patients with advanced GISTs who had received ripretinib across seven medical centers, namely Jiangsu Provincial Hospital, Jiangsu Cancer Hospital, Nanjing Drum Tower Hospital Affiliated to Nanjing University, Sir Run Run Shaw Hospital of Zhejiang University, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and the General Hospital of the People's Liberation Army, from 1 June 2021 to 31 March 2024. The cohort included 48 men and 31 women, 19 of whom had received ripretinib as second-line, 13 as third-line, and 47 as fourth-line therapy. Two peripheral venous blood samples were obtained from each participant and high-performance liquid chromatography-tandem mass spectrometry used to determine peak (Cmax) and trough (Cmin) concentrations of ripretinib. Machine learning methodologies, specifically the K-nearest neighbor algorithm combined with the Gridsearch CV strategy, were employed to establish the threshold for Cmin. We analyzed adverse reactions, treatment efficacy, median progression-free survival (mPFS), and the relationship between drug blood concentration and selected clinical parameters. &lt;b&gt;Results:&lt;/b&gt; In the entire cohort, the Cmin and Cmax of ripretinib were 467 ± 360 μg/L and 986 ± 493 μg/L, respectively. Notably, female patients and individuals in the high-dose group exhibited significantly higher values for both Cmin and Cmax (both &lt;i&gt;P&lt;/i&gt;&lt;0.05). However, variations in drug concentrations associated with the line of ripretinib therapy, treatment efficacy, disease progression, and presence of selected specific genetic mutations were not significantly associated with values of Cmin and Cmax (&lt;i&gt;P&lt;/i&gt;&gt;0.05). Among the 79 patients with advanced GISTs receiving ripretinib, reported adverse reactions included alopecia (53, 67.09%), hand-foot syndrome (24, 30.38%), fatigue (22, 27.85%), and myalgia (21, 26.58%). Two patients (2.53%) had grade III complications, both classified as hand-foot syndrome. The correlation between Cmax and adverse reactions was not statistically significant (&lt;i&gt;P&lt;/i&gt; &gt; 0.05). By the time of the latest follow-up, five deaths (6.3%) had occurred within the cohort. The mPFS for the group was 16.3 months, with a mPFS of 14.4 months fo","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 11","pages":"1133-1140"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Completely laparoscopic radical treatment of distal gastric cancer through natural orifice specimen extraction surgery: past, present, and future]. [通过自然腔道标本摘取手术对远端胃癌进行完全腹腔镜根治术:过去、现在和未来]。
Q3 Medicine Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn441530-20240312-00091
W W Li, D B Ding, R P Liang, H Huang, Y Zhao, B Wei

Gastric cancer is a prevalent malignancy of the digestive system, and traditional laparoscopic radical gastrectomy remains a crucial treatment modality. However, the abdominal wound associated with specimen removal during this procedure conflicts with contemporary concept of minimally invasive surgery. Natural orifice specimen extraction surgery (NOSES) is an emerging minimally invasive surgical technique that has gained increasing utilization in patients with gastrointestinal tumors, owing to its benefits of reduced wound, accelerated postoperative recovery, and diminished postoperative pain. In recent years, the extensive application of NOSES technology for colorectal cancer in China has provided theoretical support for the minimally invasive treatment of gastric cancer. With the standardization of community health examinations in China, the incidence of early gastric cancer diagnoses is expected to rise, making NOSES surgery the likely future trend in the surgical treatment for early gastric cancer. However, this area remains under-explored both domestically and internationally. This paper aims to synthesize prior literature and review the historical development, current research status, advantages and disadvantages, technical challenges, and future directions of completely laparoscopic radical treatment of distal gastric cancer utilizing NOSES.

胃癌是一种常见的消化系统恶性肿瘤,传统的腹腔镜根治性胃切除术仍是一种重要的治疗方式。然而,这种手术中与标本取出相关的腹部伤口与当代微创手术的理念相冲突。自然孔标本取出术(NOSES)是一种新兴的微创手术技术,由于其具有减少伤口、加快术后恢复和减轻术后疼痛等优点,在胃肠道肿瘤患者中的应用越来越广泛。近年来,NOSES技术在我国结直肠癌的广泛应用,为胃癌的微创治疗提供了理论支持。随着中国社区健康检查的规范化,早期胃癌的诊断率有望上升,NOSES手术可能成为未来早期胃癌外科治疗的趋势。然而,国内外对这一领域的研究仍然不足。本文旨在综合先前的文献,回顾利用NOSES进行全腹腔镜远端胃癌根治术的历史发展、研究现状、优缺点、技术挑战和未来方向。
{"title":"[Completely laparoscopic radical treatment of distal gastric cancer through natural orifice specimen extraction surgery: past, present, and future].","authors":"W W Li, D B Ding, R P Liang, H Huang, Y Zhao, B Wei","doi":"10.3760/cma.j.cn441530-20240312-00091","DOIUrl":"10.3760/cma.j.cn441530-20240312-00091","url":null,"abstract":"<p><p>Gastric cancer is a prevalent malignancy of the digestive system, and traditional laparoscopic radical gastrectomy remains a crucial treatment modality. However, the abdominal wound associated with specimen removal during this procedure conflicts with contemporary concept of minimally invasive surgery. Natural orifice specimen extraction surgery (NOSES) is an emerging minimally invasive surgical technique that has gained increasing utilization in patients with gastrointestinal tumors, owing to its benefits of reduced wound, accelerated postoperative recovery, and diminished postoperative pain. In recent years, the extensive application of NOSES technology for colorectal cancer in China has provided theoretical support for the minimally invasive treatment of gastric cancer. With the standardization of community health examinations in China, the incidence of early gastric cancer diagnoses is expected to rise, making NOSES surgery the likely future trend in the surgical treatment for early gastric cancer. However, this area remains under-explored both domestically and internationally. This paper aims to synthesize prior literature and review the historical development, current research status, advantages and disadvantages, technical challenges, and future directions of completely laparoscopic radical treatment of distal gastric cancer utilizing NOSES.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 11","pages":"1172-1177"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Onco-metabolic surgery: the bridge between curative resection of gastric cancer and the remission of type 2 diabetes mellitus]. [肿瘤代谢手术:胃癌根治性切除与 2 型糖尿病缓解之间的桥梁]。
Q3 Medicine Pub Date : 2024-11-25 DOI: 10.3760/cma.j.cn441530-20231217-00224
L J Cheng, Z P Wu, Y H Qiao, Y S Jiang, L Xiang, L N Wu, B S Guan, H L Tang, S F Huang, J G Yang

The close relationship between gastric cancer (GC) and type 2 diabetes mellitus (T2DM) has garnered significant attention. On one hand, T2DM may play a role in the development and progression of GC, correlating with poor patient outcomes. On the other hand, after radical surgery for GC, T2DM can be effectively managed, potentially improving tumor prognosis. In recent years, bariatric and metabolic surgery (BMS) has revolutionized T2DM treatment for obese and overweight patients. Comparative analyses reveal similarities between surgical approaches for gastric cancer and BMS, leading to the emergence of the onco-metabolic surgery (OMS) concept, which suggests that radical tumor resection and T2DM remission in GC patients can be potentially achieved through a single procedure. However, there are notable differences between OMS and BMS, including target populations, surgical details, and perioperative management. Therefore, optimizing the application of the OMS concept in GC patients holds significant clinical importance. This article provides a review to facilitate the better implementation of this concept in practice.

胃癌(GC)与 2 型糖尿病(T2DM)之间的密切关系备受关注。一方面,T2DM 可能在胃癌的发生和发展过程中起作用,并与患者的不良预后相关。另一方面,在 GC 根治术后,T2DM 可得到有效控制,从而改善肿瘤预后。近年来,减肥和代谢手术(BMS)彻底改变了肥胖和超重患者的 T2DM 治疗。对比分析显示,胃癌手术方法与减肥代谢手术方法有相似之处,因此出现了减肥代谢手术(OMS)的概念,即胃癌患者可通过一次手术实现肿瘤根治性切除和 T2DM 缓解。然而,OMS 与 BMS 在目标人群、手术细节和围手术期管理等方面存在明显差异。因此,优化 OMS 概念在 GC 患者中的应用具有重要的临床意义。本文对这一概念进行了综述,以便在实践中更好地实施这一概念。
{"title":"[Onco-metabolic surgery: the bridge between curative resection of gastric cancer and the remission of type 2 diabetes mellitus].","authors":"L J Cheng, Z P Wu, Y H Qiao, Y S Jiang, L Xiang, L N Wu, B S Guan, H L Tang, S F Huang, J G Yang","doi":"10.3760/cma.j.cn441530-20231217-00224","DOIUrl":"10.3760/cma.j.cn441530-20231217-00224","url":null,"abstract":"<p><p>The close relationship between gastric cancer (GC) and type 2 diabetes mellitus (T2DM) has garnered significant attention. On one hand, T2DM may play a role in the development and progression of GC, correlating with poor patient outcomes. On the other hand, after radical surgery for GC, T2DM can be effectively managed, potentially improving tumor prognosis. In recent years, bariatric and metabolic surgery (BMS) has revolutionized T2DM treatment for obese and overweight patients. Comparative analyses reveal similarities between surgical approaches for gastric cancer and BMS, leading to the emergence of the onco-metabolic surgery (OMS) concept, which suggests that radical tumor resection and T2DM remission in GC patients can be potentially achieved through a single procedure. However, there are notable differences between OMS and BMS, including target populations, surgical details, and perioperative management. Therefore, optimizing the application of the OMS concept in GC patients holds significant clinical importance. This article provides a review to facilitate the better implementation of this concept in practice.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 11","pages":"1178-1185"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Impacts of participation in surgical clinical trial on safety and survival outcomes in patients with right-sided colon cancer]. [参加外科临床试验对右侧结肠癌患者安全性和生存结果的影响]。
Q3 Medicine Pub Date : 2024-09-25 DOI: 10.3760/cma.j.cn441530-20240129-00048
H Q Zhang, G Q Wang, B Wu, G L Lin, H Z Qiu, B Z Niu, J Y Lu, L Xu, X Y Sun, G N Zhang, Y Xiao
<p><p><b>Objective:</b> To explore the impact on safety and prognosis in patients with right-sided colon cancer participating in surgical clinical research. <b>Methods:</b> This retrospective cohort study utilized data from a randomized controlled trial (RELARC study) conducted by the colorectal surgery group at Peking Union Medical College Hospital in which laparoscopic complete mesocolic excision (CME) was compared with D2 radical resection for the management of right-sided colon cancer. The eligibility criteria were age 18-75 years, biopsy-proven colon adenocarcinoma, tumor located between the cecum and right 1/3 of the transverse colon, enhanced chest, abdomen, and pelvic CT scans suggesting tumor stage T2-T4N0M0 or TanyN+ M0, and having undergone radical surgical treatment from January 2016 to December 2019. Exclusion factors included multiple primary colorectal cancers, preoperative stage T1N0 or enlarged central lymph nodes, tumor involving surrounding organs requiring their resection, definite distant metastasis or otherwise unable to undergo R0 resection, history of any other malignant tumors within previous 5 years, intestinal obstruction, perforation, or gastrointestinal bleeding requiring emergency surgery, and assessed as unsuitable for laparoscopic surgery. Patients who had participated in the RELARC study were included in the RELARC group, whereas those who met the inclusion criteria but refused to participate in the RELAEC study were included in the control group. The main indicators studied were the patient's baseline data, surgery and perioperative conditions, pathological characteristics, adjuvant treatment, and postoperative follow-up (including average frequency of follow-up within the first 3 years) and survival (including 3-year disease-free survival rate (DFS) and 3-year overall survival rate (OS). Differences in these indicators between the RELARC and control groups were compared. <b>Results:</b> The study cohort comprised 290 patients, 173 in the RELARC group (RELARC-CME group, 82; RELARC-D2 group, 91) and 117 in the control group (CME control group, 72; D2 control group, 45). There was a significantly higher proportion of overweight patients (BMI ≥24 kg/m<sup>2</sup>) in the RELARC-CME than in the CME control group (67.1% [55/82] vs. 33.3% [24/72], χ<sup>2</sup>=17.469, <i>P</i><0.001). There were no other statistically significant differences in baseline characteristics (all <i>P</i>>0.05). No significant disparities were found between the CME and D2 groups in terms of operation duration, intraoperative blood loss, rate of conversion to open surgery, combined organ resection, intraoperative blood transfusion, or intraoperative complications (all <i>P</i>>0.05). There was a trend toward Clavien-Dindo grade II or higher postoperative complications in the RELARC-CME group (24.4% [20/82]) than in the CME control group (18.1% [13/72]); however, this difference was not statistically significant (χ<sup>2</sup>=0.914, <i>P</i>
目的探讨参与外科临床研究的右侧结肠癌患者对安全性和预后的影响。方法: 采用随机对照试验(RELARC 研究)的数据进行回顾性队列研究:这项回顾性队列研究利用了北京协和医院结直肠外科小组开展的一项随机对照试验(RELARC 研究)的数据,该试验比较了腹腔镜完整结肠系膜切除术(CME)和 D2 根治性切除术治疗右侧结肠癌的效果。入选标准为年龄18-75岁,活检证实为结肠腺癌,肿瘤位于盲肠和横结肠右1/3之间,胸部、腹部和盆腔CT增强扫描提示肿瘤分期为T2-T4N0M0或TanyN+ M0,2016年1月至2019年12月期间接受过根治性手术治疗。排除因素包括:多发性原发性结直肠癌、术前分期T1N0或中央淋巴结肿大、肿瘤累及周围器官需要切除、明确远处转移或因其他原因无法进行R0切除、前5年内有任何其他恶性肿瘤病史、肠梗阻、穿孔或消化道出血需要紧急手术,以及经评估不适合腹腔镜手术。参加过RELARC研究的患者被纳入RELARC组,而符合纳入标准但拒绝参加RELAEC研究的患者被纳入对照组。研究的主要指标包括患者的基线数据、手术和围手术期情况、病理特征、辅助治疗、术后随访(包括前3年的平均随访频率)和生存率(包括3年无病生存率(DFS)和3年总生存率(OS))。比较了 RELARC 组和对照组在这些指标上的差异。研究结果研究队列由 290 名患者组成,其中 RELARC 组 173 人(RELARC-CME 组 82 人;RELARC-D2 组 91 人),对照组 117 人(CME 对照组 72 人;D2 对照组 45 人)。RELARC-CME组超重患者(体重指数≥24 kg/m2)的比例明显高于CME对照组(67.1% [55/82] vs. 33.3% [24/72],χ2=17.469,PP>0.05)。CME组和D2组在手术时间、术中失血量、转为开放手术率、合并器官切除、术中输血和术中并发症等方面没有发现明显差异(均P>0.05)。与CME对照组(18.1% [13/72])相比,RELARC-CME组(24.4% [20/82])的术后并发症呈Clavien-Dindo II级或更高的趋势,但这一差异无统计学意义(χ2=0.914,P=0.339)。同样,这一比例在 RELARC-D2 组(25.3% [23/91])和 D2 对照组(24.4% [11/45],χ2=0.011,P=0.916)之间也没有明显差异。RELARC组术后随访的中位持续时间明显短于相应的对照组。具体来说,RELARC-CME组的中位随访时间为4.5(4.5,4.5)个月,CME对照组为7.2(6.0,9.0)个月(Z=-10.608,PZ=-10.595,PP>0.05)。根据病理分期进行的亚组分析显示,pN0 期的 RELARC-D2 组患者的 3 年 OS 率明显高于 D2 对照组(100% 对 88.9%,P=0.008)。我们发现,其余亚组之间的生存率差异无统计学意义(P>0.05)。结论:这是一项高质量的外科临床试验:密切随访的高质量外科临床试验可实现围手术期的安全性和改善生存结果的趋势。
{"title":"[Impacts of participation in surgical clinical trial on safety and survival outcomes in patients with right-sided colon cancer].","authors":"H Q Zhang, G Q Wang, B Wu, G L Lin, H Z Qiu, B Z Niu, J Y Lu, L Xu, X Y Sun, G N Zhang, Y Xiao","doi":"10.3760/cma.j.cn441530-20240129-00048","DOIUrl":"10.3760/cma.j.cn441530-20240129-00048","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the impact on safety and prognosis in patients with right-sided colon cancer participating in surgical clinical research. &lt;b&gt;Methods:&lt;/b&gt; This retrospective cohort study utilized data from a randomized controlled trial (RELARC study) conducted by the colorectal surgery group at Peking Union Medical College Hospital in which laparoscopic complete mesocolic excision (CME) was compared with D2 radical resection for the management of right-sided colon cancer. The eligibility criteria were age 18-75 years, biopsy-proven colon adenocarcinoma, tumor located between the cecum and right 1/3 of the transverse colon, enhanced chest, abdomen, and pelvic CT scans suggesting tumor stage T2-T4N0M0 or TanyN+ M0, and having undergone radical surgical treatment from January 2016 to December 2019. Exclusion factors included multiple primary colorectal cancers, preoperative stage T1N0 or enlarged central lymph nodes, tumor involving surrounding organs requiring their resection, definite distant metastasis or otherwise unable to undergo R0 resection, history of any other malignant tumors within previous 5 years, intestinal obstruction, perforation, or gastrointestinal bleeding requiring emergency surgery, and assessed as unsuitable for laparoscopic surgery. Patients who had participated in the RELARC study were included in the RELARC group, whereas those who met the inclusion criteria but refused to participate in the RELAEC study were included in the control group. The main indicators studied were the patient's baseline data, surgery and perioperative conditions, pathological characteristics, adjuvant treatment, and postoperative follow-up (including average frequency of follow-up within the first 3 years) and survival (including 3-year disease-free survival rate (DFS) and 3-year overall survival rate (OS). Differences in these indicators between the RELARC and control groups were compared. &lt;b&gt;Results:&lt;/b&gt; The study cohort comprised 290 patients, 173 in the RELARC group (RELARC-CME group, 82; RELARC-D2 group, 91) and 117 in the control group (CME control group, 72; D2 control group, 45). There was a significantly higher proportion of overweight patients (BMI ≥24 kg/m&lt;sup&gt;2&lt;/sup&gt;) in the RELARC-CME than in the CME control group (67.1% [55/82] vs. 33.3% [24/72], χ&lt;sup&gt;2&lt;/sup&gt;=17.469, &lt;i&gt;P&lt;/i&gt;&lt;0.001). There were no other statistically significant differences in baseline characteristics (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). No significant disparities were found between the CME and D2 groups in terms of operation duration, intraoperative blood loss, rate of conversion to open surgery, combined organ resection, intraoperative blood transfusion, or intraoperative complications (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). There was a trend toward Clavien-Dindo grade II or higher postoperative complications in the RELARC-CME group (24.4% [20/82]) than in the CME control group (18.1% [13/72]); however, this difference was not statistically significant (χ&lt;sup&gt;2&lt;/sup&gt;=0.914, &lt;i&gt;P&lt;/i&gt;","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 9","pages":"928-937"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Chinese expert consensus on the surgical treatment of right-sided colon cancer (2024 edition)]. [右侧结肠癌外科治疗中国专家共识(2024 年版)]。
Q3 Medicine Pub Date : 2024-09-25 DOI: 10.3760/cma.j.cn441530-20240817-00287

In the past two decades, with the development and application of laparoscopic technique and the promotion of the concept of complete mesocolic excision, significant changes have occurred in the surgical treatment of right-sided colon cancer. The Chinese Society of Colorectal Surgery and Chinese Colorectal Research Consortium (CCRC) Organized national experts in colorectal surgery to form a consensus on 14 key clinical issues related to right hemicolectomy, taking into account the preferences of Chinese doctors and patients as well as the pros and cons of intervention measures, with a view to standardizing the surgical treatment of right colon cancer. The consensus recommendations were focused on three main aspects: (1) surgical anatomy: the key structures and its definitions related to the mesentery and vascular anatomy were clarified. It is recommended that the left side of the superior mesenteric artery be considered the medial boundary for complete mesocolic excision; (2) surgical technique: laparoscopy is recommended as the preferred surgical approach for right-sided colon cancer; (3) surgical principles: D2 lymph node dissection could be considered as the standard of care for right-sided colon cancer. Standard D2 could be considered as routine procedure unless preoperative imaging or intraoperative exploration revealed suspected regional lymph node metastasis. Dissection of infrapyloric lymph node is not recommended unless it is suspected as metastasis. Additionally, consensus recommendations were made regarding the location of vascular ligation, the extent of bowel resection, and anastomosis techniques.

近二十年来,随着腹腔镜技术的发展和应用,以及全系膜切除理念的推广,右半结肠癌的外科治疗发生了重大变化。中华医学会结直肠外科学分会和中国结直肠研究联盟(CCRC)组织全国结直肠外科专家,结合我国医生和患者的偏好以及干预措施的利弊,就右半结肠切除术相关的 14 个关键临床问题形成共识,以期规范右半结肠癌的外科治疗。共识建议主要集中在三个方面:(1)手术解剖:明确了肠系膜和血管解剖相关的关键结构及其定义。建议将肠系膜上动脉左侧作为完整切除肠系膜的内侧边界;(2)手术技术:建议将腹腔镜作为右侧结肠癌的首选手术方法;(3)手术原则:D2 淋巴结清扫术可视为右侧结肠癌的标准治疗方法。除非术前造影或术中探查发现疑似区域淋巴结转移,否则可将标准 D2 作为常规手术。除非怀疑有转移,否则不建议切除幽门下淋巴结。此外,还就血管结扎的位置、肠切除范围和吻合技术提出了共识性建议。
{"title":"[Chinese expert consensus on the surgical treatment of right-sided colon cancer (2024 edition)].","authors":"","doi":"10.3760/cma.j.cn441530-20240817-00287","DOIUrl":"10.3760/cma.j.cn441530-20240817-00287","url":null,"abstract":"<p><p>In the past two decades, with the development and application of laparoscopic technique and the promotion of the concept of complete mesocolic excision, significant changes have occurred in the surgical treatment of right-sided colon cancer. The Chinese Society of Colorectal Surgery and Chinese Colorectal Research Consortium (CCRC) Organized national experts in colorectal surgery to form a consensus on 14 key clinical issues related to right hemicolectomy, taking into account the preferences of Chinese doctors and patients as well as the pros and cons of intervention measures, with a view to standardizing the surgical treatment of right colon cancer. The consensus recommendations were focused on three main aspects: (1) surgical anatomy: the key structures and its definitions related to the mesentery and vascular anatomy were clarified. It is recommended that the left side of the superior mesenteric artery be considered the medial boundary for complete mesocolic excision; (2) surgical technique: laparoscopy is recommended as the preferred surgical approach for right-sided colon cancer; (3) surgical principles: D2 lymph node dissection could be considered as the standard of care for right-sided colon cancer. Standard D2 could be considered as routine procedure unless preoperative imaging or intraoperative exploration revealed suspected regional lymph node metastasis. Dissection of infrapyloric lymph node is not recommended unless it is suspected as metastasis. Additionally, consensus recommendations were made regarding the location of vascular ligation, the extent of bowel resection, and anastomosis techniques.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 9","pages":"879-890"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A case report of Roux-en-Y gastric bypass combined with radical gastrectomy for severe obesity complicated with gastric cancer]. [Roux-en-Y胃旁路术联合根治性胃切除术治疗严重肥胖并发胃癌的病例报告]。
Q3 Medicine Pub Date : 2024-09-25 DOI: 10.3760/cma.j.cn441530-20231020-00142
J D Li, J C Zhang, J M Wu, Z Y Dong, N Cai, C C Wang
{"title":"[A case report of Roux-en-Y gastric bypass combined with radical gastrectomy for severe obesity complicated with gastric cancer].","authors":"J D Li, J C Zhang, J M Wu, Z Y Dong, N Cai, C C Wang","doi":"10.3760/cma.j.cn441530-20231020-00142","DOIUrl":"10.3760/cma.j.cn441530-20231020-00142","url":null,"abstract":"","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 9","pages":"978-979"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comprehensive evaluation of single-anastomosis duodenal-ileal bypass with sleeve gastrectomy in obese patients based on efficacy and nutrition]. [肥胖患者单吻合十二指肠-回肠旁路术联合袖带胃切除术的疗效和营养综合评估]。
Q3 Medicine Pub Date : 2024-09-25 DOI: 10.3760/cma.j.cn441530-20230810-00041
L F Hu, L Wang, S X Li, Y Liu, Z Zhang, M H Xiao, Z H Zhang, Z Q Wei, L Cui, T Jiang
<p><p><b>Objective:</b> To evaluate the 1-year postoperative efficacy and nutritional indicators of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) in obese patients. <b>Methods:</b> This retrospective observational study included patients with a body mass index (BMI) of ≥40.0 kg/m<sup>2</sup> regardless of other related metabolic diseases and patients with severe type 2 diabetes and a BMI between 27.5 and 40.0 kg/m<sup>2</sup>. The clinical data of 66 obese patients who underwent SADI-S at the Bariatric and Metabolic Surgery Department of China-Japan Union Hospital of Jilin University from November 2018 to May 2022 were collected, including 53 cases of da Vinci robotic surgery and 13 cases of laparoscopic surgery. The patients comprised 38 men and 28 women with a median age of 35 (18-61) years and a mean preoperative BMI of 42.93 ± 6.82 kg/m<sup>2</sup>. A total of 38 patients had type 2 diabetes, and 46 had hyperuricemia, 45 had hypertension, 35 had hyperlipidemia, 12 had hypercholesterolemia, and 12 had a high low-density lipoprotein (LDL) level. The main observation indicators were (1) intraoperative and postoperative conditions; (2) weight loss outcomes, including body weight, BMI, excess body weight loss (%EWL), and total body weight loss (%TWL) at 3, 6, and 12 months after surgery; (3) effects of treatment on metabolic disease; and (4) changes in nutrient indicators. <b>Results:</b> (1) Intraoperative and postoperative conditions: All patients successfully underwent SADI-S with neither conversion to laparotomy nor death. Four (6.1%) patients developed postoperative complications, and all of them recovered and were discharged after conservative or surgical treatment. (2) Weight loss outcomes: %EWL at 3, 6, and 12 months after surgery was 62.07 ± 26.56, 85.93 ± 27.92, and 106.65 ± 29.65, respectively, and %TWL was 22.67 ± 4.94, 32.10 ± 5.18, and 40.56 ± 7.89, respectively. Body weight and BMI 3 to 12 months after surgery were significantly lower than those before surgery (all <i>P</i> < 0.001). (3) Effect of treatment on metabolic disease: 3 to 12 months after surgery, fasting blood sugar, HbA1c, uric acid, systolic blood pressure, diastolic blood pressure, triglycerides, total cholesterol, LDL, and other indicators were significantly lower than those before surgery (all <i>P</i> < 0.05). Twelve months after surgery, the remission rates of diabetes, hyperuricemia, hypertension, hypertriglyceridemia, hypercholesterolemia, and high LDL were 100% (38/38), 65.2% (30/46), 62.2% (28/45), 94.3% (33/35), 100% (12/12), and 100% (12/12), respectively. (4) Changes in nutrient indicators: Compared with the preoperative nutrient levels, the hemoglobin and hematocrit levels were lower at 3 to 12 months after surgery, the total protein level was lower at 6 to 12 months after surgery, the albumin level was lower at 6 months after surgery, and the ferritin level was lower at 3 months after surgery. The differences were statistically
目的评估肥胖患者单吻合十二指肠-回肠旁路袖带胃切除术(SADI-S)术后 1 年的疗效和营养指标。研究方法:这项回顾性观察研究纳入了体重指数(BMI)≥40.0 kg/m2且无其他相关代谢疾病的患者,以及体重指数在 27.5 至 40.0 kg/m2 之间的严重 2 型糖尿病患者。收集了2018年11月至2022年5月在吉林大学中日联谊医院减重与代谢外科接受SADI-S手术的66例肥胖患者的临床资料,其中达芬奇机器人手术53例,腹腔镜手术13例。患者中男性38例,女性28例,中位年龄35(18-61)岁,术前平均体重指数(BMI)为42.93±6.82 kg/m2。共有 38 名患者患有 2 型糖尿病,46 名患者患有高尿酸血症,45 名患者患有高血压,35 名患者患有高脂血症,12 名患者患有高胆固醇血症,12 名患者患有高低密度脂蛋白(LDL)水平。主要观察指标为:(1)术中和术后情况;(2)体重减轻结果,包括术后3、6和12个月的体重、体重指数(BMI)、超重体重减轻率(%EWL)和总体重减轻率(%TWL);(3)治疗对代谢性疾病的影响;(4)营养指标的变化。结果:(1)术中和术后情况:所有患者都成功接受了 SADI-S,既没有转为开腹手术,也没有死亡。4例(6.1%)患者出现术后并发症,经保守或手术治疗后全部康复出院。(2)体重减轻结果:术后3、6和12个月的EWL%分别为(62.07 ± 26.56)、(85.93 ± 27.92)和(106.65 ± 29.65),TWL%分别为(22.67 ± 4.94)、(32.10 ± 5.18)和(40.56 ± 7.89)。术后 3 至 12 个月的体重和 BMI 均明显低于术前(均 P <0.001)。(3)治疗对代谢疾病的影响:术后3至12个月,空腹血糖、HbA1c、尿酸、收缩压、舒张压、甘油三酯、总胆固醇、低密度脂蛋白等指标均明显低于术前(均P<0.05)。术后12个月,糖尿病、高尿酸血症、高血压、高甘油三酯血症、高胆固醇血症和高低密度脂蛋白的缓解率分别为100%(38/38)、65.2%(30/46)、62.2%(28/45)、94.3%(33/35)、100%(12/12)和100%(12/12)。(4) 营养指标的变化:与术前营养水平相比,术后 3 至 12 个月的血红蛋白和血细胞比容水平较低,术后 6 至 12 个月的总蛋白水平较低,术后 6 个月的白蛋白水平较低,术后 3 个月的铁蛋白水平较低。这些差异均有统计学意义(P<0.05)。贫血的发生率为 6.1%(4/66),低白蛋白血症的发生率为 4.5%(3/66),铁蛋白缺乏的发生率为 4.5%(3/66),所有这些症状都在保守治疗后得到改善或恢复正常。术后 12 个月,30(45.5%)名患者出现维生素 A 缺乏症,17(25.8%)名患者出现维生素 E 缺乏症,11(16.7%)名患者出现叶酸缺乏症,2 名患者出现钾缺乏症(3.0%),3(4.5%)名患者出现钙缺乏症,2(3.0%)名患者出现镁缺乏症,9(13.6%)名患者出现铁缺乏症,16(24.2%)名患者出现锌缺乏症。但是,没有出现相关的临床症状。结论SADI-S 对减轻体重和缓解代谢性疾病有非常明显的效果。SADI-S 后的营养缺乏主要涉及维生素 A、维生素 E、锌和叶酸。SADI-S 的长期疗效和安全性仍需进一步跟踪观察。
{"title":"[Comprehensive evaluation of single-anastomosis duodenal-ileal bypass with sleeve gastrectomy in obese patients based on efficacy and nutrition].","authors":"L F Hu, L Wang, S X Li, Y Liu, Z Zhang, M H Xiao, Z H Zhang, Z Q Wei, L Cui, T Jiang","doi":"10.3760/cma.j.cn441530-20230810-00041","DOIUrl":"10.3760/cma.j.cn441530-20230810-00041","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the 1-year postoperative efficacy and nutritional indicators of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) in obese patients. &lt;b&gt;Methods:&lt;/b&gt; This retrospective observational study included patients with a body mass index (BMI) of ≥40.0 kg/m&lt;sup&gt;2&lt;/sup&gt; regardless of other related metabolic diseases and patients with severe type 2 diabetes and a BMI between 27.5 and 40.0 kg/m&lt;sup&gt;2&lt;/sup&gt;. The clinical data of 66 obese patients who underwent SADI-S at the Bariatric and Metabolic Surgery Department of China-Japan Union Hospital of Jilin University from November 2018 to May 2022 were collected, including 53 cases of da Vinci robotic surgery and 13 cases of laparoscopic surgery. The patients comprised 38 men and 28 women with a median age of 35 (18-61) years and a mean preoperative BMI of 42.93 ± 6.82 kg/m&lt;sup&gt;2&lt;/sup&gt;. A total of 38 patients had type 2 diabetes, and 46 had hyperuricemia, 45 had hypertension, 35 had hyperlipidemia, 12 had hypercholesterolemia, and 12 had a high low-density lipoprotein (LDL) level. The main observation indicators were (1) intraoperative and postoperative conditions; (2) weight loss outcomes, including body weight, BMI, excess body weight loss (%EWL), and total body weight loss (%TWL) at 3, 6, and 12 months after surgery; (3) effects of treatment on metabolic disease; and (4) changes in nutrient indicators. &lt;b&gt;Results:&lt;/b&gt; (1) Intraoperative and postoperative conditions: All patients successfully underwent SADI-S with neither conversion to laparotomy nor death. Four (6.1%) patients developed postoperative complications, and all of them recovered and were discharged after conservative or surgical treatment. (2) Weight loss outcomes: %EWL at 3, 6, and 12 months after surgery was 62.07 ± 26.56, 85.93 ± 27.92, and 106.65 ± 29.65, respectively, and %TWL was 22.67 ± 4.94, 32.10 ± 5.18, and 40.56 ± 7.89, respectively. Body weight and BMI 3 to 12 months after surgery were significantly lower than those before surgery (all &lt;i&gt;P&lt;/i&gt; &lt; 0.001). (3) Effect of treatment on metabolic disease: 3 to 12 months after surgery, fasting blood sugar, HbA1c, uric acid, systolic blood pressure, diastolic blood pressure, triglycerides, total cholesterol, LDL, and other indicators were significantly lower than those before surgery (all &lt;i&gt;P&lt;/i&gt; &lt; 0.05). Twelve months after surgery, the remission rates of diabetes, hyperuricemia, hypertension, hypertriglyceridemia, hypercholesterolemia, and high LDL were 100% (38/38), 65.2% (30/46), 62.2% (28/45), 94.3% (33/35), 100% (12/12), and 100% (12/12), respectively. (4) Changes in nutrient indicators: Compared with the preoperative nutrient levels, the hemoglobin and hematocrit levels were lower at 3 to 12 months after surgery, the total protein level was lower at 6 to 12 months after surgery, the albumin level was lower at 6 months after surgery, and the ferritin level was lower at 3 months after surgery. The differences were statistically ","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 9","pages":"945-952"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical characteristics, treatment strategy, and clinical outcomes in type 2 intestinal failure]. [2型肠衰竭的临床特征、治疗策略和临床结果]。
Q3 Medicine Pub Date : 2024-09-25 DOI: 10.3760/cma.j.cn441530-20231222-00229
X L Ge, W L Qi, W Liu, H L Xu, L N Ye, Q Cao, N Li, W Zhou

Objective: To evaluate the characteristics, clinical management and clinical outcomes of type 2 intestinal failure (IF). Methods: A descriptive case-control study was carried out. The inclusion criteria were as follows: (1) the diagnosis of IF was performed according to the European Society for Parenteral and Enteral Nutrition (ESPEN) consensus statement. (2) using a requirement for parenteral nutrition (PN) of 28 days or more as surrogate marker. (3) a multidisciplinary team (MDT) included surgeons, nutritionist, pharmacist, stoma therapists, and critical care physicians. (4) complete laboratory data. Patients with type 1 and type 3 IF and those who do not cooperate with follow-up. All the data of 67 type II IF were collected from the database in Sir Run Run Shaw Hospital from Jan 2016 to Dec 2023. The pathophysiology, clinical management, and outcomes of type II IF were analyzed. Results: A total of 67 type II IF were included. The median age was 54 (15-83) with 43 males and 24 females. The body mass index was (17.5±3.8) kg/m2, the incidence of malnutrition was 67.2% (45/67), the incidence of sarcopenia was 74.6% (50/67), the median number of previous surgeries was 2.0 (1-13), and the median duration time of PN was 2.1 (1-12) months. The underlying disease of type 2 IF included 36 Crohn`s disease, 2 ulcerative colitis, 3 radiation enteritis, 2 intestinal Behcet's disease, 4 mesenteric infarction, 1 aggressive fibromatosis, 5 abdominal cocoon syndrome, 5 gastrointestinal perforation, 1 hernia, 4 intestinal dysmotility, and 4 other reasons (gastrointestinal tumor, trauma, and non-Hodgkin's lymphoma). According to the pathophysiology of IF, there were 33 intestinal fistula, 12 intestinal dysmotility, 6 mechanical obstruction, 13 short bowel syndrome, and 3 extensive small bowel mucosal disease. After treatment with MDT, 67 patients with type 2 IF received nutritional support therapy for intestinal rehabilitation treatment, of which 36 patients recovered with oral diet or enteral nutrition, 31 patients underwent reconstructive surgery after intestinal rehabilitation treatment failure. The median duration time of reconstructive surgery was 2.7 (1-9) months. 24 patients recovered intestinal autonomy after surgery, with 7 deaths, including 6 deaths due to abdominal infections and 1 case of intestinal dysmotility with abiotrophy and liver failure. Conclusion: Standardized multidisciplinary treatment plays an important role in type II intestinal failure, and it promotes patients with intestinal failure regain enteral autonomy.

目的评估 2 型肠功能衰竭(IF)的特征、临床管理和临床结果。方法: 采用描述性病例对照研究:进行了一项描述性病例对照研究。纳入标准如下(1) 根据欧洲肠外和肠内营养学会(ESPEN)的共识声明进行 IF 诊断。(2) 以需要肠外营养(PN)28 天或更长时间作为替代指标。(3) 多学科团队(MDT)包括外科医生、营养师、药剂师、造口治疗师和重症监护医生。(4) 完整的实验室数据。1 型和 3 型 IF 患者以及不配合随访的患者。从邵逸夫医院的数据库中收集了 2016 年 1 月至 2023 年 12 月期间 67 例 II 型 IF 的所有数据。分析了II型IF的病理生理学、临床治疗和预后。结果:共纳入 67 例 II 型 IF。中位年龄为 54 岁(15-83 岁),其中男性 43 人,女性 24 人。体重指数为(17.5±3.8)kg/m2,营养不良发生率为 67.2%(45/67),肌少症发生率为 74.6%(50/67),既往手术次数中位数为 2.0(1-13)次,PN 持续时间中位数为 2.1(1-12)个月。2 型 IF 的基础疾病包括:克罗恩病 36 例、溃疡性结肠炎 2 例、放射性肠炎 3 例、肠白塞氏病 2 例、肠系膜梗塞 4 例、侵袭性纤维瘤病 1 例、腹部蚕茧综合征 5 例、胃肠穿孔 5 例、疝气 1 例、肠道运动障碍 4 例以及其他原因 4 例(胃肠道肿瘤、外伤和非霍奇金淋巴瘤)。根据 IF 的病理生理学,有 33 例肠瘘、12 例肠运动障碍、6 例机械性梗阻、13 例短肠综合征和 3 例广泛的小肠粘膜病变。67 名 2 型 IF 患者在接受 MDT 治疗后,接受了肠道康复治疗的营养支持疗法,其中 36 名患者通过口服饮食或肠内营养康复,31 名患者在肠道康复治疗失败后接受了重建手术。重建手术的中位持续时间为 2.7(1-9)个月。24 名患者在手术后恢复了肠道自主功能,7 人死亡,其中 6 人死于腹部感染,1 人因肠道运动障碍并伴有非营养不良和肝功能衰竭而死亡。结论是规范化多学科治疗在 II 型肠衰竭中发挥着重要作用,可促进肠衰竭患者恢复肠道自主功能。
{"title":"[Clinical characteristics, treatment strategy, and clinical outcomes in type 2 intestinal failure].","authors":"X L Ge, W L Qi, W Liu, H L Xu, L N Ye, Q Cao, N Li, W Zhou","doi":"10.3760/cma.j.cn441530-20231222-00229","DOIUrl":"10.3760/cma.j.cn441530-20231222-00229","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the characteristics, clinical management and clinical outcomes of type 2 intestinal failure (IF). <b>Methods:</b> A descriptive case-control study was carried out. The inclusion criteria were as follows: (1) the diagnosis of IF was performed according to the European Society for Parenteral and Enteral Nutrition (ESPEN) consensus statement. (2) using a requirement for parenteral nutrition (PN) of 28 days or more as surrogate marker. (3) a multidisciplinary team (MDT) included surgeons, nutritionist, pharmacist, stoma therapists, and critical care physicians. (4) complete laboratory data. Patients with type 1 and type 3 IF and those who do not cooperate with follow-up. All the data of 67 type II IF were collected from the database in Sir Run Run Shaw Hospital from Jan 2016 to Dec 2023. The pathophysiology, clinical management, and outcomes of type II IF were analyzed. <b>Results:</b> A total of 67 type II IF were included. The median age was 54 (15-83) with 43 males and 24 females. The body mass index was (17.5±3.8) kg/m<sup>2</sup>, the incidence of malnutrition was 67.2% (45/67), the incidence of sarcopenia was 74.6% (50/67), the median number of previous surgeries was 2.0 (1-13), and the median duration time of PN was 2.1 (1-12) months. The underlying disease of type 2 IF included 36 Crohn`s disease, 2 ulcerative colitis, 3 radiation enteritis, 2 intestinal Behcet's disease, 4 mesenteric infarction, 1 aggressive fibromatosis, 5 abdominal cocoon syndrome, 5 gastrointestinal perforation, 1 hernia, 4 intestinal dysmotility, and 4 other reasons (gastrointestinal tumor, trauma, and non-Hodgkin's lymphoma). According to the pathophysiology of IF, there were 33 intestinal fistula, 12 intestinal dysmotility, 6 mechanical obstruction, 13 short bowel syndrome, and 3 extensive small bowel mucosal disease. After treatment with MDT, 67 patients with type 2 IF received nutritional support therapy for intestinal rehabilitation treatment, of which 36 patients recovered with oral diet or enteral nutrition, 31 patients underwent reconstructive surgery after intestinal rehabilitation treatment failure. The median duration time of reconstructive surgery was 2.7 (1-9) months. 24 patients recovered intestinal autonomy after surgery, with 7 deaths, including 6 deaths due to abdominal infections and 1 case of intestinal dysmotility with abiotrophy and liver failure. <b>Conclusion:</b> Standardized multidisciplinary treatment plays an important role in type II intestinal failure, and it promotes patients with intestinal failure regain enteral autonomy.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 9","pages":"966-969"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Membrane anatomy-toward a new era of pelvic surgery]. [膜解剖学--迈向盆腔手术新时代]。
Q3 Medicine Pub Date : 2024-09-25 DOI: 10.3760/cma.j.cn441530-20240704-00234
H L Liu, H H Jiang, M B Lin

The concept of membrane anatomy has been widely accepted and applied in clinical practice, but there are still many theoretical and practical conflicts. This article elucidates the fundamental concepts and manifestations of membrane anatomy, delineating its comprehensive integration of anatomical and surgical disciplines. Thereafter, this article specifically discusses its differences from the traditional anatomy and surgery, and then clarifies the important role of membrane anatomy as the third generation of surgical anatomy and the new surgical concept for the development of pelvic surgery.

膜解剖学的概念已被广泛接受并应用于临床实践,但仍存在许多理论和实践上的冲突。本文阐明了膜解剖学的基本概念和表现形式,划分了其与解剖学和外科学的全面融合。随后,本文具体论述了其与传统解剖学和外科学的区别,进而阐明了膜解剖学作为第三代外科解剖学和新的外科理念对盆腔外科发展的重要作用。
{"title":"[Membrane anatomy-toward a new era of pelvic surgery].","authors":"H L Liu, H H Jiang, M B Lin","doi":"10.3760/cma.j.cn441530-20240704-00234","DOIUrl":"10.3760/cma.j.cn441530-20240704-00234","url":null,"abstract":"<p><p>The concept of membrane anatomy has been widely accepted and applied in clinical practice, but there are still many theoretical and practical conflicts. This article elucidates the fundamental concepts and manifestations of membrane anatomy, delineating its comprehensive integration of anatomical and surgical disciplines. Thereafter, this article specifically discusses its differences from the traditional anatomy and surgery, and then clarifies the important role of membrane anatomy as the third generation of surgical anatomy and the new surgical concept for the development of pelvic surgery.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"27 9","pages":"891-897"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华胃肠外科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1